164 related articles for article (PubMed ID: 31915455)
1. iTRAQ-Based Proteomics Analysis of Plasma of Myasthenia Gravis Patients Treated with Jia Wei Bu Zhong Yi Qi Decoction.
Zhang Y; Yang J; Chen Y; Lv J; Zhang J; Zhang Y; Zhao X; Fang H; Liu C; Zhang Q; Cui X; Wang X; Gao F
Evid Based Complement Alternat Med; 2019; 2019():9147072. PubMed ID: 31915455
[TBL] [Abstract][Full Text] [Related]
2. A screening strategy for bioactive components of Bu-Zhong-Yi-Qi-Tang regulating spleen-qi deficiency based on "endobiotics-targets-xenobiotics" association network.
Hu L; Chen J; Duan H; Zou Z; Qiu Y; Du J; Chen J; Yao X; Kiyohara H; Nagai T; Yao Z
J Ethnopharmacol; 2023 Oct; 314():116605. PubMed ID: 37178982
[TBL] [Abstract][Full Text] [Related]
3. [Effects of Bu Zhong Yi Qi decoction on CIH-induced interstitial lung fibrosis in mice].
Tang Y; Liu BB; Chen Q; Li TT; Ji ES; Li JR
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2022 Sep; 38(5):559-563. PubMed ID: 37088770
[TBL] [Abstract][Full Text] [Related]
4. Bu-zhong-yi-qi pill alleviate the chemotherapy-related fatigue in 4 T1 murine breast cancer model.
Ouyang M; Liu Y; Tan W; Xiao Y; Yu K; Sun X; Huang Y; Cheng J; Luo R; Zhao X
BMC Complement Altern Med; 2014 Dec; 14():497. PubMed ID: 25511260
[TBL] [Abstract][Full Text] [Related]
5. Proteomics analysis reveals suppression of IL-17 signaling pathways contributed to the therapeutic effects of Jia-Wei Bu-Shen-Yi-Qi formula in a murine asthma model.
Qin J; Wuniqiemu T; Wei Y; Teng F; Cui J; Sun J; Yi L; Tang W; Zhu X; Xu W; Dong J
Phytomedicine; 2022 Jan; 95():153803. PubMed ID: 34785105
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the restorative effect of Bu-zhong-yi-qi-tang in the spleen-qi deficiency rat model using (1)H-NMR-based metabonomics.
Zheng XF; Tian JS; Liu P; Xing J; Qin XM
J Ethnopharmacol; 2014 Feb; 151(2):912-20. PubMed ID: 24333365
[TBL] [Abstract][Full Text] [Related]
7. The clinical application and pharmacological mechanism of Bu-Zhong-Yi-Qi decoction for treating cancer-related fatigue: An overview.
Li G; Ding J; Zhang Y; Wang X
Biomed Pharmacother; 2022 Dec; 156():113969. PubMed ID: 36411646
[TBL] [Abstract][Full Text] [Related]
8. Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.
Caifeng S; Jingsheng Z; Yi L; Xueshi H; Zhanyou W; Haiou P; Wenjun Q
J Tradit Chin Med; 2022 Oct; 42(5):810-817. PubMed ID: 36083490
[TBL] [Abstract][Full Text] [Related]
9. Antiinflammatory effects of Bu-zhong-yi-qi-tang in patients with perennial allergic rhinitis.
Yang SH; Yu CL
J Ethnopharmacol; 2008 Jan; 115(1):104-9. PubMed ID: 17980528
[TBL] [Abstract][Full Text] [Related]
10. Identification and Verification of Two Novel Differentially Expressed Proteins from Non-neoplastic Mucosa and Colorectal Carcinoma Via iTRAQ Combined with Liquid Chromatography-Mass Spectrometry.
Bai Y; Wang J; Gao Z; Dai E
Pathol Oncol Res; 2020 Apr; 26(2):967-976. PubMed ID: 30927204
[TBL] [Abstract][Full Text] [Related]
11. [New exploration of treatment target for proliferative diabetic retinopathy based on iTRAQ LC-MS/MS Proteomics].
Wen DJ; Ren XJ; Dong LJ; He Y; Li XR
Zhonghua Yan Ke Za Zhi; 2019 Oct; 55(10):769-776. PubMed ID: 31607066
[No Abstract] [Full Text] [Related]
12. Identification of human serum protein targets of Qianggu Decoction () in primary type I osteoporosis based on tandem mass tag labeling and liquid chromatography-tandem mass spectrometry technology.
Liang BC; Shi XL; Li CW; Shi ZY; He WT; Yao JL; Kong LC; Li XY
Chin J Integr Med; 2017 Oct; 23(10):747-754. PubMed ID: 27389089
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomics analysis with iTRAQ in human lenses with nuclear cataracts of different axial lengths.
Zhou H; Yan H; Yan W; Wang X; Ma Y; Wang J
Mol Vis; 2016; 22():933-43. PubMed ID: 27559289
[TBL] [Abstract][Full Text] [Related]
14. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.
Yao X; Xia F; Tang W; Xiao C; Yang M; Zhou B
J Ethnopharmacol; 2018 Feb; 212():208-215. PubMed ID: 29031784
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of multiple bioactive components of Bu-zhong-yi-qi-tang in rat tissues by LC-MS/MS: Application to a tissue distribution study.
He M; Chen W; Wang M; Wu Y; Zeng J; Zhang Z; Shen S; Jiang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Feb; 1044-1045():177-184. PubMed ID: 28113140
[TBL] [Abstract][Full Text] [Related]
16. In vivo metabolic profiles of Bu-Zhong-Yi-Qi-Tang, a famous traditional Chinese medicine prescription, in rats by ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry.
Hu L; Yao Z; Qin Z; Liu L; Song X; Dai Y; Kiyohara H; Yamada H; Yao X
J Pharm Biomed Anal; 2019 Jul; 171():81-98. PubMed ID: 30981193
[TBL] [Abstract][Full Text] [Related]
17. Bu-Zhong-Yi-Qi Granule Enhances Colonic Tight Junction Integrity via TLR4/NF-
Kang X; Jia M; Zhao L; Zhang S
Evid Based Complement Alternat Med; 2021; 2021():6657141. PubMed ID: 33763148
[TBL] [Abstract][Full Text] [Related]
18. [1H NMR based metabolomics study of bu-zhong-yi-qi-tang in the spleen-qi deficiency rat model].
Chen L; Xiang H; Xing J; Tian JS; Qin XM; Du GH
Yao Xue Xue Bao; 2014 Sep; 49(9):1320-5. PubMed ID: 25518333
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteome analysis of saccular intracranial aneurysms with iTRAQ quantitative proteomics.
Wang J; Yu L; Huang X; Wang Y; Zhao J
J Proteomics; 2016 Jan; 130():120-8. PubMed ID: 26385002
[TBL] [Abstract][Full Text] [Related]
20. iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin's Lymphoma.
Yu R; Cheng L; Yang S; Liu Y; Zhu Z
Front Oncol; 2022; 12():848286. PubMed ID: 35371990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
